GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: drug combo trial underway
Disease control OngoingThis study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 22:49 UTC
-
New drug cocktail shows promise for common lymphoma
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with untreated stage III-IV follicular lymphoma. The goal is to see if the combo can shrink or eliminate tumors and keep the cancer under control. Participants must have measur…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug combo shows promise for lymphoma patients
Disease control OngoingThis study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how many patients have their cancer shrink or disappear. The trial involves 30 adults with certain types of lymp…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New triple therapy shows promise for common blood cancer
Disease control OngoingThis study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) works better than standard treatments for people with untreated follicular lymphoma, a slow-growing blood cancer. About 40 adults with stage II to IV disease will receive the drug comb…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 36 adults will take part i…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug acalabrutinib to CAR T-cell therapy (a treatment that uses a patient's own immune cells to fight cancer) is safe and effective for adults with certain types of B-cell lymphoma. About 23 participants will receive the combination. The goal i…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control OngoingThis study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and understand side effects. About 22 ad…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC